Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tideglusib · 1 trial · 2 indications
Change in mean PVC count per 24 hours on 7-day Holter
| Arm | Type | Description |
|---|---|---|
| Tideglusib | ACTIVE_COMPARATOR | Randomization to Tideglusib 1g po daily or matching placebo |
| Placebo | PLACEBO_COMPARATOR | Randomization to matching placebo 1g po daily |
| Name | Type | Description |
|---|---|---|
| Tideglusib | DRUG | Tideglusib 1g po daily |
| Placebo | DRUG | Matching placebo 1g po daily |
Inclusion Criteria: * A pathogenic or likely pathogenic desmosomal (PKP2, DSG2, DSC2, DSP, or JUP\*) rare variant OR the TMEM43-p.S358L variant \*JUP carriers must be homozygous or compound heterozygous * Mean ≥ 500 PVCs per 24 hours on a baseline screening 7-day Holter monitor * Clinical ACM di...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Lexeo Therapeutics, Inc. | LXEO | 3 | PHASE1 | LX2020 |
Tideglusib is an investigational small molecule being studied for the treatment of Arrhythmogenic Cardiomyopathy, including Arrhythmogenic Right Ventricular Cardiomyopathy. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
Tideglusib is a glycogen synthase kinase-3 (GSK-3) inhibitor. It is being evaluated in a targeted therapy approach for Arrhythmogenic Cardiomyopathy, with biomarker-selected patient enrollment in the ongoing clinical trial.
Tideglusib is being developed by Rhythm Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol RYTM. The company is conducting a Phase 2 clinical trial for this drug in Arrhythmogenic Cardiomyopathy.
Tideglusib is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is actively recruiting participants in Canada.
Tideglusib is being studied in a single Phase 2 clinical trial registered as NCT06174220, titled "Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy." This randomized, double-blind, placebo-controlled trial is recruiting 120 adult participants in Canada.
Yes, Tideglusib is a glycogen synthase kinase-3 (GSK-3) inhibitor. The ongoing Phase 2 trial specifically evaluates this targeted therapy approach for Arrhythmogenic Cardiomyopathy, and the study is designed to enroll patients selected based on biomarkers.